Publications by authors named "Zhining Dong"

Article Synopsis
  • Psoriasis is a chronic skin condition with no established serum biomarkers for diagnosis or treatment; this study investigates Peptidase inhibitor 3 (PI3) levels as a potential biomarker across various patient groups and healthy controls.* -
  • Results show that PI3 levels can effectively differentiate psoriasis patients from other conditions, revealing high accuracy rates (AUCs), and significantly correlate with disease severity as measured by the Psoriasis Area Severity Index (PASI).* -
  • The study finds that patients with higher PI3 levels are more likely to resist treatment, with a significant odds ratio, and that PI3 levels decrease substantially in patients who respond well to treatment after 12 weeks.*
View Article and Find Full Text PDF

Objective: To evaluate the analytical performance of our previously developed chemiluminescence immunoassay (CLIA) kit for the detection of procalcitonin (PCT) and compare with the results obtained using the Vidas B.R.A.

View Article and Find Full Text PDF

Neutrophil gelatinase-associated lipocalin (NGAL) is a promising biomarker for diagnosing acute kidney injury (AKI). Currently, there are few assays for determining NGAL and they are complex, time-consuming or expensive. We aimed to establish an efficient immunoassay to measure NGAL in human urine simply and rapidly.

View Article and Find Full Text PDF

The morbidity and mortality associated with acute kidney injury (AKI) remain obstinately high. Early diagnosis is urgently required and should be pursued in at-risk populations. Recently, a newly validated biomarker, matrix metalloproteinase-7 (MMP-7), was reported as a novel indicator for early AKI prediction and a noninvasive surrogate biomarker of kidney function.

View Article and Find Full Text PDF

Quantitative hepatitis B core antigen (anti-HBc) measurements could play an important role in evaluating therapeutic outcomes and optimizing the antiviral therapy of chronic hepatitis B infection. In this study, we have developed a simple and rapid fluorescence point-of-care test based on a lateral flow immunoassay (LFIA) method integrated with Eu (III) chelate microparticles to quantitatively determine anti-HBc concentrations in serum. This assay is based on a direct competitive immunoassay performed on lateral flow test strips with an assay time of 15 min.

View Article and Find Full Text PDF

Glypican-3(GPC3), an oncofetal protein, is a potential novel marker for hepatocellular carcinoma (HCC). In this study, we attempted to establish a new method to detect serum GPC3 using the antibodies identified in our previous research, and then evaluated its clinical application for the diagnosis of HCC. Herein, a sandwich time-resolved fluorescence immunoassay (TRFIA) for detecting serum GPC3 was developed.

View Article and Find Full Text PDF

In this paper, a novel time-resolved fluorescence immunoassay (TRFIA) is described that allows the simultaneous quantitative detection of hepatitis B virus surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in human serum to aid the diagnosis and monitoring of hepatitis B virus infection. The proposed method was developed based on a two-step sandwich immunoassay protocol in which monoclonal antibodies against HBsAg and HBeAg were co-coated in 96 microtitration wells, then tracer polyclonal antibodies against HBsAg labeled with samarium and tracer monoclonal antibodies against HBeAg labeled with europium chelates were used for detection. The detection range was 0.

View Article and Find Full Text PDF

The isoenzyme creatine kinase MB is very important for diagnosis of acute myocardial infarction (AMI). Some CK-MB immunoassays are sensitive, accurate and available for clinical application, but they are expensive and time-consuming procedures. Furthermore, conventional fluorescence immunochromatographic assays (FL-ICAs) have suffered from background fluorescence interference and low analytical sensitivity.

View Article and Find Full Text PDF

Enzyme-linked immunosorbent assay (ELISAs) specific for Epstein-Barr virus nuclear antigen 1 (EBNA1)-immunoglobulin A (IgA) are most commonly used in the clinical diagnosis of EBV infection. But they have a low sensitivity and the enzyme-labeled antibodies are unstable. In this study, a novel immunoassay based on an indirect time-resolved fluoroimmunoassay (TRFIA) was developed.

View Article and Find Full Text PDF

Objectives: This study established a novel time-resolved fluorescence immunoassay (TRFIA) that allows the simultaneous determination of rubella virus (RV) IgM and cytomegalovirus (CMV) IgM in human serum.

Design And Methods: Lanthanum elements labeled antibody and streptavidin-biotin system were used in the "capture sandwich" format simultaneously.

Results: The working range of TRFIA for RV IgM was 2-80 AU/mL and for CMV IgM was 5-400 AU/mL.

View Article and Find Full Text PDF

Enzyme-linked immunosorbent assays (ELISA) specific for anti-HSV glycoprotein G (gG) are most commonly used in the clinical diagnosis of HSV infection. But most of them are qualitative and with narrow detection ranges. A novel time-resolved fluoroimmunoassay (TRFIA) methodology was developed for the quantitative determination of HSV IgG in human serum.

View Article and Find Full Text PDF

We developed a TR-FIA kit for quantitative detection of CA50. This study aims to evaluate the analytical and clinical performances of this kit. Precision, accuracy, specificity, sensitivity, stability, and endogenous interference of this kit are evaluated.

View Article and Find Full Text PDF
Article Synopsis
  • Hepatitis B virus (HBV) is a significant health threat, and the hepatitis B surface antigen (HBsAg) is crucial for diagnosing infections, necessitating a precise and efficient testing method.
  • A new assay called AlphaLISA was created to measure HBsAg, utilizing monoclonal antibodies to ensure sensitivity to virus mutants and optimize testing conditions.
  • The AlphaLISA assay showed excellent performance with a detection range of 0.04 to 100 IU/ml and a sensitivity of 0.01 IU/ml, outperforming traditional tests and paving the way for future biomarker developments.
View Article and Find Full Text PDF

Background: Cytokeratin 19 fragment antigen (CYFRA 21-1) is used to diagnose and monitor neoplasms. However, the main disadvantages of the currently available CYFRA 21-1 assays include heterogenous technology, being time-consuming, and having low through-put with low insensitivity. This study investigated the use of amplified luminescent proximity homogeneous immunoassay (AlphaLISA) for the quantization of CYFRA 21-1 in human serum.

View Article and Find Full Text PDF

Measurement of the free β subunit of human chorionic gonadotropin (free β-hCG) in serum is useful for prenatal screening. Concentrations of free β-hCG vary in different races. Conventional assays used for such measurements have limitations.

View Article and Find Full Text PDF

We developed a luminescent terbium sensor (LTS) based on energy resonance transfer for homogeneous bioassays. The effect of temperature on photoluminescence and time-resolved fluorescence of the LTS was investigated. When the temperature was increased from 277 K to 369 K, the photoluminescence quantum yield decreased by up to 25 %, time-resolved fluorescence decreased by up to 54 %, and the lifetime shortened dramatically.

View Article and Find Full Text PDF

Objective: To develop an amplified luminescent proximity homogeneous immunoassay (AlphaLISA) kit for the detection of human hepatitis B virus e antibody (HBeAb).

Methods: The neutralizing and competitive inhibition method was used to develop the AlphaLISA kit for detection of serum HBeAb.

Results: The working range of the kit was 0.

View Article and Find Full Text PDF

Objective: To prepare a time-resolved fluoroimmunoassay (TRFIA) kit for clinical detection of IgM antibodies to hepatitis B core antigen (HBc).

Methods: Immunocapture method was used to develop the TRFIA kit for detection of the anti-HBc IgM antibodies, and the precision, cross-reactivity and sensitivity of the kit were tested with the clinical serum samples.

Results: The intra- and inter-assay coefficients of variation of the TRFIA kit were 4.

View Article and Find Full Text PDF